BIOMIND LABS INC. (3XI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BIOMIND LABS INC. (3XI) has a cash flow conversion efficiency ratio of 0.025x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-38.70K) by net assets (€-1.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BIOMIND LABS INC. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how BIOMIND LABS INC.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BIOMIND LABS INC. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BIOMIND LABS INC. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ODI PHARMA AB
F:6OD
|
N/A |
|
Raja Ferry Port Public Company Limited
BK:RP
|
0.059x |
|
Vertical Explorations Inc
V:VERT
|
-0.030x |
|
ICZOOM Group Inc. Class A Ordinary Shares
NASDAQ:IZM
|
0.083x |
|
Coloseum Holding a.s.
PR:COLOS
|
N/A |
|
Aurora Investment Trust plc
LSE:ARR
|
0.004x |
|
ASOS Plc
LSE:ASC
|
0.700x |
|
Infomedia Press Limited
NSE:INFOMEDIA
|
-0.001x |
Annual Cash Flow Conversion Efficiency for BIOMIND LABS INC. (2021–2024)
The table below shows the annual cash flow conversion efficiency of BIOMIND LABS INC. from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-1.30 Million | €-354.43K | 0.273x | -49.03% |
| 2023-12-31 | €-1.43 Million | €-765.93K | 0.535x | -93.84% |
| 2022-12-31 | €-247.66K | €-2.15 Million | 8.685x | +997.29% |
| 2021-12-31 | €2.19 Million | €-2.12 Million | -0.968x | -- |
About BIOMIND LABS INC.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical tria… Read more